Beijing Konruns PharmaceuticalLtd Future Growth
Future criteria checks 3/6
Beijing Konruns PharmaceuticalLtd is forecast to grow earnings and revenue by 21.5% and 18% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 7.3% in 3 years.
Key information
21.5%
Earnings growth rate
20.7%
EPS growth rate
Pharmaceuticals earnings growth | 18.3% |
Revenue growth rate | 18.0% |
Future return on equity | 7.3% |
Analyst coverage | Low |
Last updated | 14 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,556 | 295 | N/A | 402 | 2 |
12/31/2025 | 1,283 | 235 | N/A | 339 | 2 |
12/31/2024 | 1,077 | 186 | N/A | 320 | 2 |
3/31/2024 | 954 | 166 | 126 | 229 | N/A |
12/31/2023 | 920 | 150 | 98 | 199 | N/A |
9/30/2023 | 999 | 146 | 67 | 134 | N/A |
6/30/2023 | 946 | 112 | 51 | 97 | N/A |
3/31/2023 | 876 | 81 | -10 | 77 | N/A |
12/31/2022 | 867 | 101 | 23 | 120 | N/A |
9/30/2022 | 801 | 114 | 61 | 201 | N/A |
6/30/2022 | 726 | 130 | -38 | 152 | N/A |
3/31/2022 | 755 | 130 | -96 | 82 | N/A |
12/31/2021 | 810 | 148 | -108 | 56 | N/A |
9/30/2021 | 855 | 179 | -141 | -20 | N/A |
6/30/2021 | 916 | 180 | -141 | -54 | N/A |
3/31/2021 | 949 | 216 | -24 | 28 | N/A |
12/31/2020 | 809 | 183 | 8 | 58 | N/A |
9/30/2020 | 855 | 204 | 83 | 119 | N/A |
6/30/2020 | 870 | 220 | 186 | 208 | N/A |
3/31/2020 | 944 | 249 | 238 | 255 | N/A |
12/31/2019 | 1,066 | 266 | 243 | 262 | N/A |
9/30/2019 | 1,038 | 311 | 266 | 285 | N/A |
6/30/2019 | 1,029 | 313 | 303 | 317 | N/A |
3/31/2019 | 982 | 273 | 308 | 327 | N/A |
12/31/2018 | 973 | 264 | 246 | 263 | N/A |
9/30/2018 | 897 | 215 | 250 | 273 | N/A |
12/31/2017 | 591 | 479 | N/A | 270 | N/A |
12/31/2016 | 346 | 192 | N/A | 148 | N/A |
12/31/2015 | 436 | 195 | N/A | 192 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603590's forecast earnings growth (21.5% per year) is above the savings rate (2.9%).
Earnings vs Market: 603590's earnings (21.5% per year) are forecast to grow slower than the CN market (22% per year).
High Growth Earnings: 603590's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603590's revenue (18% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 603590's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603590's Return on Equity is forecast to be low in 3 years time (7.3%).